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Introduction and historical perspective
Between Starzl’s initial demonstration of the feasibility of
human liver transplantation (LT) in the 1960s and the
initial clinical use of cyclosporine in 1978, LT was consid-
ered an experimental procedure [1]. Liver procurement
and allocation were initially conducted within single
transplant hospitals and decisions to use donated liver
grafts were made for locally managed patients, without
much consideration for broader need at a regional or
national level. The standardization of brain death criteria
allowed donor organs to be physiologically maintained
after declaration of death, making them available to trans-
plant candidates outside of the immediate donor hospital
environment [1]. This led to the need to prioritize LT
candidates and create a systematic organ distribution sys-
tem.
Ad hoc systems and the rise of waiting time as a primary
allocation criterion
Until the National Organ Transplant Act (NOTA) was
enacted in 1984 in the United States (US), there were no
formal guidelines for determining priority on the LT
waiting list [2]. LT prioritization schemes followed the
example set in renal transplantation, offering transplants
to those who had been waiting longest [1,3]. Individual
transplant programs evaluated patients and applied non-
standardized transplant eligibility criteria. Passage of
NOTA ushered in the era of governmental oversight and
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Summary
Liver transplantation has undergone a rapid evolution from a high-risk experi-
mental procedure to a mainstream therapy for thousands of patients with a
wide range of hepatic diseases. Its increasing success has been accompanied by
progressive imbalance between organ donor supply and the patients who might
benefit. Where demand outstrips supply in transplantation, a system of organ
allocation is inevitably required to make the wisest use of the available, but
scarce, organs. Early attempts to rationally allocate donor livers were particu-
larly hampered by lack of available and suitable data, leading to imperfect solu-
tions that created or exacerbated inequities in the system. The advent and
maturation of evidence-based predictors of waiting list mortality risk led to
more objective criteria for liver allocation, aided by the increasing availability
of data on large numbers of patients. Until now, the vast majority of allocation
systems for liver transplantation have relied on estimation of waiting list
mortality. Evidence-based allocation systems that incorporate measures of
post-transplant outcomes are conceptually attractive and these transplant bene-
fit-based allocation systems have been developed, modeled, and subjected
to computer simulation. Future implementations of benefit-based liver alloca-
tion await continued refinement and additional debate in the transplant com-
munity.
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regulation of transplantation through the creation of an
Organ Procurement and Transplantation Network
(OPTN), charged with creating national policies for organ
allocation and distribution. These fledgling policies con-
tinued to emphasize waiting time, but a vocal minority of
clinicians advocated a system that ordered patients by dis-
ease severity. The resulting medical urgency status system
led to more acutely ill patients being given higher priority
categorizations for donor liver eligibility, even for donors
beyond the local area [1,3,4]. Status designations were
based first on whether the patient required emergent
transplant (Status 1) and nonemergent patients were fur-
ther categorized based on the location of their medical
management, as a presumed surrogate for disease severity:
intensive care unit (ICU) (Status 2), non-ICU hospital
inpatient (Status 3) or outpatient (Status 4) [1,4]. These
status categories comprised extremely broad ranges of dis-
ease severity and waiting time remained the primary
means to rank patients within each status designation.
The location-based status designation system was suscep-
tible to subtle and sometimes overt manipulation by
transplant providers [1].
Incorporation of the Child-Turcotte-Pugh score into
allocation policy
The allocation system was subsequently amended and
new policies evolved from 1996 to 1999 [3]. The status-
based system was preserved, along with priority for
patients with acute liver failure and primary LT nonfunc-
tion. However, the arbitrary nature of the location-based
designations for candidates with chronic liver disease
was altered to incorporate levels of the more objective
Child-Turcotte-Pugh (CTP) score [3,4], a well-established
arbiter of mortality risk for cirrhotic patients undergoing
surgical procedures [5] (Table 1).
Despite using CTP score as the main criterion for sta-
tus designation (Table 2), waiting time dominated alloca-
tion sequence, because it was retained as the main
ordering tool for candidates of the same blood type
within each status level. As a result of geographical differ-
ences in donor availability, organ procurement organiza-
tion (OPO) performance, and waiting list practices,
waiting time to transplant for patients with similar CTP
scores became increasingly divergent across the country
[1–3,6,7] and perception persisted that the liver allocation
system was ineffective and inequitable [1,2,7].
Ultimately, the US Department of Health and Human
Services promulgated regulations in a Final Rule in the
late 1990s and for the first time required organ allocation
rules based on objective medical criteria, ideally based on
continuous measures of medical urgency [1–3,7]. The
Final Rule clearly advocated for a system that would
promote equity by reducing disparities in waiting list
outcomes. This process ultimately moved the LT commu-
nity away from a waiting time-based system by using
evidence-based analyses to define medical urgency.
Development and evolution of MELD-based liver
allocation policy
A more granular metric for medical urgency was required
to displace waiting time as the de facto allocation criterion.
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Adapted from Freeman [1].




Status 1 Fulminant hepatic failure with life expectancy <7 days
Primary graft nonfunction <7 days after liver
transplantation
Hepatic artery thrombosis <7 days after liver
transplantation
Acute decompensated Wilson’s disease
Status 2A Chronic hepatic failure, hospitalized in intensive
care unit with life expectancy <7 days; CTP score ‡10;
and (at least one of):
• Acute unrelenting variceal hemorrhage
• Hepatorenal syndrome
• Refractory ascites or hepatic hydrothorax
• Stage 3 or 4 (poorly controlled) hepatic encephalopathy
Status 2B Chronic hepatic failure, requiring continuous inpatient
medical care; CTP score ‡10; or CTP ‡7 and
(at least one of):
• Acute unrelenting variceal hemorrhage
• Hepatorenal syndrome
• Spontaneous bacterial peritonitis
• Refractory ascites or hepatic hydrothorax
Status 3 Chronic hepatic failure; CTP score ‡7, but not
meeting criteria for Status 2B
Status 7 Temporarily inactive on the waiting list
Adapted from Institute of Medicine [3].
CTP, Child-Turcotte-Pugh.
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The Model for End-stage Liver Disease (MELD) was origi-
nally developed at the Mayo Clinic as a predictor of
3-month mortality risk after transjugular intrahepatic por-
tosystemic shunt for variceal bleeding or refractory ascites
from a cohort of 231 patients [8]. Serum creatinine, biliru-
bin, international normalized ratio (INR) of prothrombin
time and etiology of the liver disease were found to be sig-
nificant and independent predictors of death. The MELD
score, subsequently employed for LT allocation policy,
utilizes the regression coefficients from the three labora-
tory values and is calculated as MELD = 10 · (0.957 loge
creatinine + 0.378 loge bilirubin + 1.12 loge INR + 0.643).
Note that the final term is a constant and does not depend
on disease etiology, which was felt to be too subjective and
controversial for inclusion.
The MELD score, validated in other patient datasets,
performed well as measured by the c-statistic, a goodness
of fit for Cox regression model analogous to the area
under the receiver operating characteristic curve of a
logistic regression model [6,9,10]. MELD predicted
3-month mortality in hospitalized patients (c-statistic
0.87) and ambulatory patients with noncholestatic (c-sta-
tistic 0.80) and cholestatic diseases (c-statistics 0.87) [10].
In a study of 3437 transplant candidates with chronic
liver disease, MELD at the time of listing was superior to
CTP in predicting waiting list mortality [6].
The MELD was developed for chronic liver disease
patients and is not suitable as an allocation criterion for
patients with conditions such as inborn errors of metabo-
lism, malignancy in the absence of cirrhosis, and other
unusual diagnoses. Hepatocellular carcinoma (HCC) is a
special case discussed below and other conditions have
been recently reviewed [11], but are not further discussed
here.
MELD-based liver allocation in the US
The MELD score was adopted on February 28, 2002 as
the liver allocation tool for chronic liver disease candi-
dates. Priority for Status 1 candidates was maintained.
However, additional arbitrary changes not based on mor-
tality risk evidence were incorporated into the form of
MELD used to administer the allocation policy [6,12].
The lower bound of bilirubin and creatinine were set at
1.0 mg/dl to avoid negative MELD scores, without any
particular objective rationale. The upper bound of serum
creatinine was set at 4 mg/dl, ostensibly to limit the
access advantage afforded to patients with renal insuffi-
ciency. Candidates receiving renal replacement therapy
(RRT) in the previous week were also given an arbitrary
serum creatinine of 4 mg/dl for calculating their MELD
score [13]. Lastly, MELD scores were capped at 40,
despite data showing that patients with MELD >40 had
higher waiting list mortality than patients with MELD of
exactly 40 [6,12,14]. A Pediatric End-Stage Liver Disease
(PELD) score was developed for children. PELD compo-
nents include age, albumin, INR and growth failure, and
although based on a completely different regression equa-
tion, the MELD and PELD scores were commingled for
allocation purposes [12].
Introduction of MELD in the US was associated with
12% reduction in waiting list registrations (particularly
among those with MELD <10), 3.5% reduction in waiting
list mortality, and an increase in transplantation rates dis-
tributed across all demographic and epidemiologic strata
[15]. Early patient and graft survival after deceased donor
LT remains unchanged despite sicker patients receiving a
higher proportion of donor livers [15].
MELD and HCC
In the early 1990s, Mazzaferro et al. prospectively studied
patients transplanted for small HCC, defined as a single
lesion <5 cm in diameter or three lesions <3 cm diameter
each (Milan criteria). The 4-year recurrence-free survival
rate was 83%, with a recurrence rate of 8% [16]. Based
on these encouraging results for patients previously
shown to have dismal outcomes, and the expectation that
patients with HCC would not have MELD scores high
enough to gain access to donor organs, the Milan criteria
were incorporated into an exception system to the
MELD-based allocation system [13]. Initially, progression
beyond the Milan criteria was equated with unsuitability
for transplant, which was presumed to lead quickly to
death.
Based upon extrapolated tumor doubling times, it was
estimated that HCC candidates with stage T1 (1 lesion
<2 cm) and stage T2 (1 lesion 2–5 cm or 2–3 nodules
all <3 cm) tumors would have a risk of progression and
waiting list dropout of 15% (equivalent to MELD 24)
and 30% (equivalent to MELD 29) respectively [13,17].
Furthermore, candidates who remained untransplanted
but within the Milan criteria were assigned a MELD
score equivalent to an additional 10% increase in mor-
tality risk every 3 months [13]. No clinical data from
actual transplant candidates were used to make these
decisions.
Not surprisingly, the rate of deceased donor LT for
HCC significantly increased in the MELD era compared
with the pre-MELD era [18]. There was a corresponding
decrease in the waiting time to transplantation and
5-month dropout from the waiting list [18]. Single center
data revealed that the 1-year waiting list dropout rate for
patients with stage T1 lesions was <10%, but >50% for
stage T2 lesions [19]. However, the cumulative propor-
tion of transplanted HCC candidates was significantly
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higher than the corresponding proportion of candidates
without HCC at similar MELD scores [20]. The excessive
priority for HCC candidates has progressively reduced
through a series of empiric policy actions. Currently,
HCC candidates with stage T1 HCC do not get additional
MELD priority and those with stage T2 HCC receive a
MELD score of 22 [13].
Allocation versus distribution
As a practical matter, organ allocation policy in the US is
actually a candidate-ordering system (allocation rules)
nested within a system of geographic tiers (distribution
rules) where the allocation rules are sequentially applied.
Distribution is accomplished via local OPOs. OPOs serve
donor hospitals and transplant programs within a defined
service area. They were created as a patchwork without
regard to equity or efficiency considerations and their
boundaries persist largely unchanged today. In addition,
regional aggregates of OPOs have been created, also with-
out any scientific rationale.
Initially, donor livers were offered to all candidates in
the local OPO service areas, in descending order of
MELD score. It was common to have candidates in adja-
cent OPO service areas with higher MELD scores than
the local recipient. This represented an apparent distor-
tion of the MELD-based system’s intent to offer donor
livers to those at highest risk of waiting list death. Addi-
tional data showed that LT provided a smaller incremen-
tal survival benefit to patients with lower MELD than
those with higher MELD (and in some cases worse sur-
vival with transplant than without) [14]. Subsequently, a
modification of the MELD-based system [21] was investi-
gated using the Liver Simulated Allocation Model [22]
developed by Arbor Research Collaborative for Health as
the contractor for the Scientific Registry of Transplant
Recipients. As a result of these analyses, distribution was
altered to offer organs to regional candidates with MELD
>15 before offering them to local candidates with MELD
<15 [14]. This important policy modification became
known as the ‘‘Share-15’’ rule.
MELD and renal function
In examining the MELD equation, serum creatinine has
the greatest impact on the overall score. It reflects the
influence of kidney dysfunction on survival in liver dis-
ease [23,24] and is influenced by treatment. Although
various combinations of creatinine, bilirubin, and INR
values produce the same score, MELD is unable to dis-
criminate between candidates with severe synthetic hepa-
tic dysfunction and well-preserved renal function versus
those with serious renal disease in the setting of well-
preserved liver function. As a result, a significantly higher
proportion of candidates with creatinine ‡2.0 mg/dl have
undergone transplant in the MELD era compared with
pre-MELD era. Moreover, the proportion of candidates
on RRT at the time of LT has also increased significantly
in MELD era [24]. The rate of combined liver and kidney
transplant doubled (2.6% in 2001 vs. 5.2% in 2005) in
the pre-MELD era [21].
We have recently shown that serum creatinine is over
weighted in the MELD formula. An updated MELD,
derived from a cohort of 38 899 candidates awaiting LT
using a time-dependent Cox regression model with
MELD components as predictors of waiting list mortal-
ity, assigns a lower weight to creatinine and INR and a
higher weight to bilirubin [23]. Updated MELD (c-sta-
tistic 0.68) performed better than existing MELD (c-sta-
tistic 0.64) in predicting overall waiting list mortality.
Moreover, this study also showed that among candidates
with the same MELD score, those with lower serum cre-
atinine have significantly higher waiting list mortality
risk compared with their counterparts with high serum
creatinine [23]. Adoption of the more accurately
weighted updated MELD formula is predicted to be
associated with reduced waiting list mortality by reorder-
ing the offers of organs to those at higher risk of wait-
ing list death. To date, however, the formula has not
been updated for allocation use.
Liver allocation in the future
Liver transplantation is generally the best option for
chronic end-stage liver disease patient survival. Merion
et al. found that post-transplant mortality (covariate-
adjusted) was approximately one-fifth that on the waiting
list [14]. Were there enough organs, it appears that most
patients would opt for LT. However, there is a wide gap
between patients awaiting LT and available donor organs,
necessitating the prioritization of patients for each avail-
able deceased donor liver.
It is now well-established that the comparison between
post-LT and waiting list survival depends strongly on
patient characteristics. When Merion et al. compared liver
waiting list and post-transplant death rates by MELD
score, the authors found that at higher MELD scores, the
difference between pre- and post-transplant mortality was
greater. Specifically, the covariate-adjusted hazard ratio
(HR) was estimated at HR = 0.04 (P < 0.001), indicating
that, all else equal, patients with MELD 40 have a 96%
reduction in mortality post-transplant, relative to not
being transplanted. For patients at lower MELD scores
(e.g., MELD < 15), the HR > 1.0 (P < 0.001), indicating
that waiting list mortality was significantly lower than
post-transplant mortality; i.e. because of the relatively low
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death rates at low MELD scores and a maximum of
1 year post-transplant follow-up available when the article
was written.
A study by Merion et al. (as alluded to in the preced-
ing paragraph) was based on a limited amount of post-
transplant follow-up. It is well-known that post-transplant
death rates are initially very high, owing to operative and
peri-operative mortality; as described in detail by Wolfe
et al. for kidney transplantation [25]. Conversely, waiting
list mortality rates demonstrate no such phenomenon.
Therefore, considering two studies of the same LT
patients, the study with longer post-transplant follow-up
should have the lower (average) post-transplant mortality
rate. Merion et al. anticipated that future studies (pre-
sumably with longer follow-up) comparing pre- and post-
LT mortality would yield more favorable results for LT
given the same MELD scores, and this was indeed later
demonstrated. Studies by Schaubel et al., Lucey et al., and
Englesbe et al. [26–29] each revealed lower MELD cate-
gory-specific post-transplant/waiting list HRs than Merion
et al., indicating greater improvement in mortality with
(versus without) a deceased donor LT.
The degree to which the population as a whole gains
from a valuable, yet scarce resource depends heavily on
the resource allocation method. This widely accepted
notion applies to the allocation of deceased donor livers.
Patient survival is not uniform across LT recipients, there
are recipient characteristics that affect graft survival [28].
Therefore, a transplant candidate’s anticipated post-trans-
plant prognosis should play a role in their prioritization
for transplantation. Conversely, the candidate’s prognosis
in the absence of transplantation should also be consid-
ered. It appears that there are two valid yet competing
criteria for prioritizing waiting list patients. It would be
undesirable to give high priority to patients with poor
post-transplant prognosis; it would be perhaps equally
undesirable to assign high priority to patients for whom
good outcomes are anticipated in the absence of trans-
plantation. The concept of transplant survival benefit is
intended to combine criteria for waiting list and post-
transplant outcomes into a single score for ranking wait-
ing list candidates.
Principles of organ allocation
Specification of the goal of an allocation system by the
transplant community and society at large is the first step
in the development of evidence-based allocation method-
ologies. In some countries, including Switzerland and the
United Kingdom, the allocation system has moved
beyond exclusive consideration of the risk of death on the
waiting list. Post-transplant outcome or benefit is inte-
grated into these systems, although they have mainly
evolved in an informal manner applied by individual
transplant programs.
Types of organ allocation schemes generally fall into
one of three categories: utility, urgency, and benefit. Sup-
pose a donor organ is to be allocated to one of three
patients on the waiting list. In Table 3, we list the most
important characteristics of the three wait-listed patients:
how long each is predicted to live if they receive the
transplant (labeled TX); if they do not receive a trans-
plant (labeled WL), and predicted survival benefit derived
from the transplant (B = TX ) WL). A utility-based allo-
cation system would rank candidates in decreasing order
of predicted post-transplant survival, in which case
patient 1 would receive the organ. An urgency-based sys-
tem would offer the organ to the patient with the worst
prognosis on the waiting list, i.e. patient 2 in our exam-
ple. A benefit-based system would allocate to the patient
with the greatest difference in post-transplant and waiting
list outcomes, namely patient 3.
The patients in Table 3 illustrate the weaknesses of the
utility- and urgency-based allocation systems. Utility-
based systems identify patients with the best post-trans-
plant prognosis; these patients may also be expected to
do well in the absence of transplant. By contrast,
urgency-based systems give top priority to patients
expected to die most quickly on the waiting list, at the
risk of selecting patients who (because of their deterio-
rated condition) are doomed with or without a trans-
plant. Transplant benefit-based allocation assigns priority
in order of how much additional lifetime the patient is
projected to receive, incorporating their predicted survival
time both with and without a transplant.
Table 3. Organ allocation schemes:














1 10 7 3 17 = 10 + 2 + 5
= 3 + (7 + 2 + 5)
2 3 2 1 15 = 7 + 3 + 5
= 1 + (7 + 2 + 5)
3 9 5 4 18 = 7 + 2 + 9
= 4 + (7 + 2 + 5)
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If the goal of an allocation system is to make the big-
gest difference to the patient population, then one would
prefer to allocate by transplant survival benefit, evident in
the last column of Table 3. Before the organ is allocated,
the total future lifetime (across all waitlisted patients)
equals the sum of the WL column; this calculation is
unaffected by whether or not the organ is actually trans-
planted. The only patient affected by the available donor
organ is the patient who receives the transplant; this
patient is expected to receive B additional years of life as
a result of the transplant. Therefore, to maximize the
additional lifetime gained by the patient population as a
whole, each transplant should be assigned to the patients
with the greatest difference in predicted number of future
years lived (with the transplant, versus without).
The primary strength of benefit-based allocation is that,
for any fixed pool of donor organs, the number of addi-
tional patient-years gained through transplantation will be
maximized. Granted, the setting we consider is very sim-
ple; but, the essential ideas carry over to much more
complicated scenarios. More complicated data structures
would imply more complex computations to predict TX,
WL, and hence, B; but our discussion thus far is agnostic
as to how exactly TX, WL and B are predicted.
Development of a liver benefit score for allocation
There has been considerable work to develop a LT sur-
vival benefit score and an excellent summary of progress
to date has been recently published [28]. In its current
form, the benefit score is computed as the difference
between 5-year predicted post-transplant lifetime and
5-year predicted future waiting list lifetime (i.e., survival
time in the absence of LT). Higher scores indicate greater
benefit, i.e., a greater difference between a candidate’s
survival prospects with the transplant versus without.
The score is donor- and recipient-specific. For each
deceased donor liver to be allocated, active waiting list
candidates would be ranked in decreasing order of the
benefit score, accounting for the effect of the specific
donor’s characteristics as well as the characteristics of the
intended recipient. Thus, the benefit score would replace
MELD as the central criterion for prioritization of LT
candidates.
Figure 1 illustrates the survival benefit score. Consider
a LT candidate active on the waiting list. Given the
patient’s characteristics and the characteristics of the
donor, we can project a predicted post-transplant survival
curve to represent the patient’s survival if (s)he receives
that organ; this is the upper curve in Fig. 1. Note that the
curve is projected out to 5 years. The area under the
post-transplant survival curve equals the predicted num-
ber of years that patient would live, out of the next
5 years, with this donor liver. Given the waiting list can-
didate’s characteristics, we can also predict survival (from
the date of offer) in the absence of LT. Predicted waiting
list survival is given by the lower curve in Fig. 1, the area
under which equals the predicted number of years the
patient will live in the absence of LT, out of the next
5 years. The survival benefit score is the area between the
predicted post-transplant and waiting list survival curves.
Liver allocation was originally based on waiting time.
The Status-based system represented a major step forward,
especially as CTP score was incorporated as an objective
measure. The MELD system represents another incremental
step forward, but remains an urgency-based allocation sys-
tem that is suboptimal for organ stewardship. The compo-
nents of the MELD score are incorrectly weighted, as noted
above, and many patient characteristics aside from MELD
and its components have proven to be significant predic-
tors of waiting list survival. Considering survival benefit,
MELD is, unfortunately, an inaccurate predictor of post-
transplant survival. For these reasons, the ordering of
Figure 1 Liver transplant survival benefit is calculated by measuring
the difference between the area under the waiting list survival curve
(light shading) and the area under the post-transplant survival curve
(dark shading) over a 5-year interval.
Figure 2 Calculated transplant benefit varies considerably by Model
for End-stage Liver Disease (MELD) score and there is marked hetero-
geneity of calculated benefit within MELD score categories. As a result
of the extensive overlap in benefit across MELD scores, candidates
would be re-ordered if transplant benefit were utilized for allocation
instead of MELD. Adapted from Schaubel DE et al. Am J Transplant
2009; 9: 970.
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waitlisted patients would change substantially under a ben-
efit-based allocation system. Two patients with identical
MELD scores may have dramatically different waiting list
survival and/or post-transplant survival and hence, very
different benefit scores (Fig. 2). A patient with a MELD 30
could have a benefit score that is less than a patient with a
MELD 20. The rank correlation between the benefit and
MELD scores is estimated at 0.67 (perfect correlation
would equal 1) which is very low considering the two mea-
sures being compared are intended to serve the same func-
tion (i.e., allocation score). We anticipate that switching
from MELD to benefit-based allocation would have imme-
diate substantial effects. Liver Simulated Allocation Model
results predicted that, based on one calendar year of experi-
ence, benefit-based allocation would result in at least 100
fewer deaths [28]. More importantly, switching from
MELD- to benefit-based allocation was predicted to pro-
duce more than 2000 additional life-years saved, consider-
ing only the first 5 years of follow-up. If maximizing
additional survival time gained via LT is the overall objec-
tive, it appears that the next logical step is toward survival
benefit-based allocation.
Conclusions
Evidence-based development of liver allocation has pro-
gressed dramatically over the past 25 years. Early ad hoc
arrangements between donor hospitals and transplant
programs have led to increasingly sophisticated metrics
designed to assess the risk of death of waiting candidates
in the absence of a transplant. In recent years, the MELD
system has become the standard for evidence-based liver
allocation in the US, as well as several countries in Eur-
ope and South America. The future of liver allocation
appears poised to incorporate more objective measures of
post-transplant outcome into allocation systems, to gauge
the incremental lifetime afforded to waiting patients
and to ensure that society makes the wisest decisions as
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